Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Single-arm, Open-label, Interventional Phase IV Study to Evaluate the Safety and Efficacy of Idursulfase (r-DNA Origin) (Elaprase™) in Indian Pediatric and Adult Population With Hunter Syndrome (Mucopolysaccharidosis II)
Conditions
Interventions
Elaprase
Locations
5
India
SAT Hospital - Govt Medical College
Thiruvananthapuram, Kerala, India
JK Lone Hospital
Jaipur, Rajasthan, India
Institute of Child Health
Kolkata, India
All India Institute of Medical Sciences (AIIMS)
New Delhi, India
Sir Gangaram Hospital
New Delhi, India
Start Date
April 21, 2022
Primary Completion Date
April 6, 2024
Completion Date
April 18, 2024
Last Updated
January 23, 2025
NCT05422482
NCT05795361
NCT01506141
NCT02412787
NCT03920540
NCT03582449
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions